LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.64 0.4

Buy Sell

Overview

Share price change

24h

Current

Min

12.16

Max

12.76

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	4.857 49.8
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+55.4% upside

Market Stats
By TradingEconomics
Market Cap	2.2B
Previous open	12.24
Previous close	12.64

News Sentiment

By Acuity

50%

150 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 maj 2026, 22:50 UTC

Earnings

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 maj 2026, 22:49 UTC

Earnings

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 maj 2026, 22:32 UTC

Earnings

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 maj 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 maj 2026, 22:57 UTC

Market Talk

Earnings

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 maj 2026, 22:26 UTC

Earnings

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure Interim Dividend A$0.50/Security

12 maj 2026, 22:24 UTC

Earnings

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 maj 2026, 22:19 UTC

Earnings

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 maj 2026, 22:13 UTC

Earnings

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 maj 2026, 22:11 UTC

Earnings

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 maj 2026, 22:11 UTC

Earnings

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 maj 2026, 22:10 UTC

Earnings

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 maj 2026, 22:08 UTC

Earnings

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 maj 2026, 22:07 UTC

Earnings

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 maj 2026, 22:05 UTC

Earnings

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

55.4% upside

12 Months Forecast

Average 20 USD 55.4%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

150 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.